Osteoporosis Treatment and Prevention for Postmenopausal Women: Current and Future Therapeutic Options

被引:28
作者
Pinkerton, Joann V. [1 ]
Thomas, Semara [1 ]
Dalkin, Alan C. [2 ]
机构
[1] Univ Virginia Hlth Syst, Dept Obstet & Gynecol, Div Midlife Hlth Ctr, Charlottesville, VA USA
[2] Univ Virginia Hlth Syst, Dept Med, Div Endocrinol & Metab, Charlottesville, VA USA
关键词
osteoporosis; bisphosphonates; raloxifene; teriparatide; bazedoxifene; denosumab; BONE-MINERAL DENSITY; MESENCHYMAL STEM-CELLS; BREAST-CANCER; ZOLEDRONIC ACID; RISK; FRACTURE; RALOXIFENE; TRIAL; BAZEDOXIFENE; TERIPARATIDE;
D O I
10.1097/GRF.0b013e3182a9fb02
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Osteoporosis, a silent disease, is often unrecognized until fracture. Lifestyle modification with nutritional counseling is recommended during menopausal transition. Bone density testing is recommended for women aged 65 years and older, younger postmenopausal women with risk factors, or to follow therapy. Bisphosphonates treat osteoporosis (prevent bone resorption). Raloxifene and hormone therapy prevent bone loss and fracture, with extraskeletal benefits. Denosumab treats osteoporosis, although bone effects reverse rapidly. Teriparatide (anabolic therapy) is considered for women at high risk of fracture. Bazedoxifene with conjugated estrogens, novel delivery of teriparatide, new parathyroid hormone proteins, anti-sclerostin antibodies, cathepsin K inhibitors, and stem cell therapies are in testing.
引用
收藏
页码:711 / 721
页数:11
相关论文
共 38 条
[11]   Sclerostin: Therapeutic Horizons Based Upon Its Actions [J].
Costa, Aline G. ;
Bilezikian, John P. .
CURRENT OSTEOPOROSIS REPORTS, 2012, 10 (01) :64-72
[12]  
Crandall CJ, 2012, COMP EFFECTIVENESS R, V53
[13]   Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial [J].
Delmas, PD ;
Ensrud, KE ;
Adachi, JD ;
Harper, KD ;
Sarkar, S ;
Gennari, C ;
Reginster, JY ;
Pols, HAP ;
Recker, RR ;
Harris, ST ;
Wu, WT ;
Genant, HK ;
Black, DM ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3609-3617
[14]   Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer [J].
Eng-Wong, J. ;
Reynolds, J. C. ;
Venzon, D. ;
Liewehr, D. ;
Gantz, S. ;
Danforth, D. ;
Liu, E. T. ;
Chow, C. ;
Zujewski, J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10) :3941-3946
[15]   Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass [J].
Guan, Min ;
Yao, Wei ;
Liu, Ruiwu ;
Lam, Kit S. ;
Nolta, Jan ;
Jia, Junjing ;
Panganiban, Brian ;
Meng, Liping ;
Zhou, Ping ;
Shahnazari, Mohammad ;
Ritchie, Robert O. ;
Lane, Nancy E. .
NATURE MEDICINE, 2012, 18 (03) :456-U159
[16]   Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity [J].
Komm, BS ;
Kharode, YP ;
Bodine, PVN ;
Harris, HA ;
Miller, CP ;
Lyttle, CR .
ENDOCRINOLOGY, 2005, 146 (09) :3999-4008
[17]  
Levis Silvina, 2012, J Manag Care Pharm, V18, pS1
[18]   Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene [J].
Martino, S ;
Cauley, JA ;
Barrett-Connor, E ;
Powles, TJ ;
Mershon, J ;
Disch, D ;
Secrest, RJ ;
Cummings, SR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (23) :1751-1761
[19]   Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday [J].
McClung, Michael ;
Harris, Steven T. ;
Miller, Paul D. ;
Bauer, Douglas C. ;
Davison, K. Shawn ;
Dian, Larry ;
Hanley, David A. ;
Kendler, David L. ;
Yuen, Chui Kin ;
Lewiecki, E. Michael .
AMERICAN JOURNAL OF MEDICINE, 2013, 126 (01) :13-20
[20]   Predictors of change in calcium intake in postmenopausal women after osteoporosis screening [J].
McLeod, Katherine M. ;
McCann, Susan E. ;
Horvath, Peter J. ;
Wactawski-Wende, Jean .
JOURNAL OF NUTRITION, 2007, 137 (08) :1968-1973